



Election/Amend A/
EXT (1) / #16
J 4.1.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application Serial No. 09/576,424

Examiner: P. Gambel

Filed: May 22, 2000

Title: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 STIMULATORY ANTIGENS

* * * * *

ELECTION REPLY

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on February 19, 2002, Applicants elect with traverse the following species corresponding to previous Group III and IV and Claims 11-20:

- (i) treatment of intestinal inflammation; and as the ultimate species
- (ii) Crohn's disease.

Also, Applicants further are submitting the following claims in lieu of current claims 1-26 directed to the elected subject matter.

--27. (New) A method of treating intestinal inflammation in a subject in need of such treatment by administering an anti-B7.1 (CD86) antibody that does not inhibit the B7.1/CTLA-4 binding interaction.

28. (New) The method of Claim 27, wherein said subject has a disease selected from the group consisting of inflammatory bowel disease (IBD), coeliac disease, eosinophilia gastroenteritis, mastocytosis, Crohn's disease, and ulcerative colitis.

29. (New) The method of Claim 28, wherein the disease is Crohn's disease.

30. (New) The method of Claim 28, wherein said antibody is administered in combination with another entity that modulates the B7/CD28 pathway.

31. (New) The method of Claim 29, wherein said moiety is selected from the group consisting of IL-7, IL-10, CTLA4-Ig, soluble CTLA-4, an anti-CD28 antibody or fragment thereof.

32. (New) The method of Claim 27, which is combined with administration of another immunosuppressant.

RECEIVED
MAR 28 2002
TECH CENTER 1600/2900

Sub CA

A1

Sub B1

Sub CA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson et al.

Appl. No.: 09 576,424

Series Code ↑

Serial No. ↑

Filed: May 22, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1644

Examiner: P. Gambel

Atty. Dkt. P 0275681 1995-30-0233CP2

M#

Client Ref

Appl. Title: Identification of Unique Binding
Interactions Between Certain Antibodies
and the Human B7.1 and B7.2
Stimulatory Antigens

Date: March 22, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input checked="" type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
		7	**minus 26	0	x \$18/\$9 =	+ \$0	103/203
		1	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add						+ \$280/\$140 =	+ \$0 104/204
5. Original due Date: March 19, 2002		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =				115/215
		(2 mos)	\$400/\$200 =		+ \$110		116/216
		(3 mos)	\$920/\$460 =				117/217
		(Usable only for ≤ 2mo.OA --- 4 mos)	\$1,440/\$720=				118/218
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1,960/\$980=				128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee Attached					+ \$110		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180	+ \$0	126
or if Rule 97(d) Request					+ \$180	+ \$0	126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$740/370	+ \$0	1179/1279
14. Petition fee for					+ \$0		
15. TOTAL FEE ENCLOSED =						\$110	

15.

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

03/26/2002 HUKMB1 00000024 09576424

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275681

C#

M#

01 FC:115

110.00 OP

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Fax:

(703) 905-2500

Tel:

(703) 905-2200

Atty/Sec: RLT/LAK

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments